Search research articles
Contact Us
Filters
Showing results (21-30 of 318) with videos related to
Page
of 32
Sort By:
Leukemia & Lymphoma
|
June 11, 2015
High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care?
Carrie van der Weyden, H Miles Prince
Expert Review of Hematology
|
September 3, 2013
Romidepsin for peripheral T-cell lymphoma
Amit Khot, Michael Dickinson, H Miles Prince
Blood
|
May 7, 2016
How I treat mycosis fungoides and Sézary syndrome
Sean Whittaker, Richard Hoppe, H Miles Prince
Expert Review of Hematology
|
June 15, 2011
Managing multiple myeloma in the elderly: are we making progress?
Hang Quach, H Miles Prince, Andrew Spencer
Future Oncology (London, England)
|
December 4, 2013
Romidepsin for cutaneous T-cell lymphoma
H Miles Prince, Michael Dickinson, Amit Khot
Drugs & Aging
|
September 28, 2007
Treatment strategies in elderly patients with multiple myeloma: current status
Hang Quach, H Miles Prince, Linda Mileshkin
Leukemia & Lymphoma
|
February 28, 2007
An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
H Miles Prince, Brad Schenkel, Linda Mileshkin
Leukemia & Lymphoma
|
February 26, 2008
The potential of histone deacetylase inhibitors for the treatment of multiple myeloma
H Miles Prince, Mark Bishton, Simon Harrison
Leukemia & Lymphoma
|
April 10, 2008
The development of novel immunotherapeutic approaches in multiple myeloma
Stefan Peinert, H Miles Prince, Simon Harrison
Expert Opinion on Investigational Drugs
|
July 6, 2013
Panobinostat in lymphoid and myeloid malignancies
Amit Khot, Michael Dickinson, H Miles Prince
Page
of 32
Search research articles
Search
Showing results (21-30 of 318) with videos related to
Sort By:
Page
of 32
Leukemia & Lymphoma
|
June 11, 2015
High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care?
Carrie van der Weyden, H Miles Prince
Expert Review of Hematology
|
September 3, 2013
Romidepsin for peripheral T-cell lymphoma
Amit Khot, Michael Dickinson, H Miles Prince
Blood
|
May 7, 2016
How I treat mycosis fungoides and Sézary syndrome
Sean Whittaker, Richard Hoppe, H Miles Prince
Expert Review of Hematology
|
June 15, 2011
Managing multiple myeloma in the elderly: are we making progress?
Hang Quach, H Miles Prince, Andrew Spencer
Future Oncology (London, England)
|
December 4, 2013
Romidepsin for cutaneous T-cell lymphoma
H Miles Prince, Michael Dickinson, Amit Khot
Drugs & Aging
|
September 28, 2007
Treatment strategies in elderly patients with multiple myeloma: current status
Hang Quach, H Miles Prince, Linda Mileshkin
Leukemia & Lymphoma
|
February 28, 2007
An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
H Miles Prince, Brad Schenkel, Linda Mileshkin
Leukemia & Lymphoma
|
February 26, 2008
The potential of histone deacetylase inhibitors for the treatment of multiple myeloma
H Miles Prince, Mark Bishton, Simon Harrison
Leukemia & Lymphoma
|
April 10, 2008
The development of novel immunotherapeutic approaches in multiple myeloma
Stefan Peinert, H Miles Prince, Simon Harrison
Expert Opinion on Investigational Drugs
|
July 6, 2013
Panobinostat in lymphoid and myeloid malignancies
Amit Khot, Michael Dickinson, H Miles Prince
Page
of 32